May 19th
The Board of Directors of Vironova AB hereby announces that it is intending to conduct a rights issue in Vironova with preferential rights. Vironova AB is now seeking underwriters to guarantee the rights issue. For more information read hear.
April 27th
The shareholders in Vironova AB (publ), 556678-1463, (the ”Company”) are hereby given notice of the Extraordinary General Meeting to be held on Wednesday, June 7, 2023 at 14:00 at the company’s premises, Gävlegatan 22, Stockholm, Sweden.
Right to participate
Shareholders who wish to participate in the Extraordinary General Meeting must be recorded in the share register kept by Euroclear Sweden AB no later than Monday, May 29, 2023 and give notice of their, and any advisors, intention to participate no later than Wednesday, May 31, 2023 at 16:00, under address: Vironova AB, Gävlegatan 22, 113 30, Stockholm or by e-mail: ir@vironova.com. The notification should state name, Personal ID number or corporate registration number and registered number of shares held.
More information regarding the Extraordinary General Meeting on 7 June.
March 15th
The decision to continue operations for Vironova AB (publ), 556678–1463 was taken at the extraordinary general meeting which was held on March 15, 2023.
February 24th
The shareholders in Vironova AB (publ), 556678–1463, (the "Company") are hereby invited to an extraordinary general meeting on Tuesday, March 14, 2023 at 14.00, in the Company's premises, Gävlegatan 22, Stockholm
A message Message from Vironova AB´s Chairman of the Board of Directors.
June 14th
The Annual General Meeting will be moved from June 30, 2022 to July 15, 2022 at 14.00. A new notice of the Annual General Meeting will be issued shortly. The Annual General Meeting will be held at the company's premises at Gävlegatan 22 in Stockholm.
Access more information, documentation, and registration for the Annual General Meeting 2022 here.
After careful consideration, the Board has decided to extend the time for acceptance of the company's offer regarding bridge financing (see The Board announcement to shareholders 1 June 2022) from 8 June, 2022, to 17 June, 2022.
June 1st 2022.
The shareholders' response has been positive but not sufficient. After careful consideration, the Board has therefore decided to extend the response time for the bridge financing offer for shareholders in Vironova AB (publ), from 31 May 2022 to 8 June 2022 at 16.00.
April 20th 2022.
Prevas has signed an agreement for the acquisition of 100 percent of BitSim NOW AB. BitSim NOW is a consulting firm in Stockholm with 35 employees focusing on innovative product development. Read more information regarding the divestment.
March 9th 2022.
The Board of Directors of Vironova AB hereby announces that it has decided on a rights issue in Vironova with preferential rights. The rights issue is fully guaranteed by the board.
Subscription period
With reference to the board´s resolution on February 8th, 2022, regarding a rights issue of shares, the board resolves to extend the subscription period until March 18th, 2022, as well as the related payment periods. The board authorizes the managing director, Mohammed Homman to extend the period further if needed.
Read more on the board of directors’ resolution here.
Founded in Stockholm in 2005, Vironova is a world leading partner to the global life science community in the development of novel therapies for tomorrow. By combining hardware and software solutions for advanced electron microscopy analysis, we support our partners through the whole value chain. From initial sample preparation to imaging and final analytical result, our dedicated team provide insightful and actionable data. We empower clients to make better-informed decisions, to create value and ensure safety for patients worldwide.
Watch the video and learn more about Vironova
The life science market is shifting. Recent successes in genetic medicine have paved the way for a broader wave of therapies and next-generation technologies. As conventional therapies mature, cell and gene therapies are emerging as the future of biopharmaceuticals, representing a pivotal approach to treat previously uncurable diseases and conditions. As a result, the global cell and gene therapy market is expected to grow from 3 to 27 billion dollars by 2025.
Development of novel therapies is a highly regulated, costly and time critical process – setting high standards for secure, reliable and intuitive systems across the entire production line. Vironova is in pole position to capture value and growth opportunities in this ever-evolving landscape. Transmission electron microscopy (TEM) paired with our intelligent software and experience, is the leading method capable of producing a reliable and accurate analysis for the development of novel therapies.
Vironova´s CEO and Founder, Mohammed Homman
A great deal of things are going on in the Vironova group and in the industry, which we trendwatch and follow. Take action and follow us on our social media channels and subscribe to our newsletter to stay up to date!
You can also follow us on Mynewsdesk for relevant news updates.
TEM has previously been an expensive and complex practice to use in gene therapy, vaccine and drug development. At Vironova, we focus on supporting our partners by lowering technical thresholds, minimizing analytical complexity and provide business critical insights for the development of biopharmaceuticals targeting previously untreatable conditions.
We are experts in what we do and put technology and innovation at our core. From initial sample preparation to imaging and final analytical result, our dedicated team will cut time and cost to market for our clients, and ultimately create value for patients worldwide. We are on a mission to build trust in the therapies of tomorrow by making the invisible visible today.
.png)
Our Mission: We are on a mission to build trust in the therapies of tomorrow by making the invisible visible today.
Vironova provides fast and cost-effective electron microscopy services enabled by our own software and hardware. Our services are performed in the world’s only GMP-certified TEM laboratory, creating reliable and traceable results. This makes us the only company with a full-service value chain offer from start to finish.
By combining deep industry expertise and data-driven insights, we help clients solve real needs by making the subvisible accessible. With over 200 established customer relationships, Vironova is a leading partner for the life science industry. We have a strong acquisition pipeline of new clients and deep inroads with the global research community.
Two of our senior scientists analyzing images for one of our clients in the world's first and only GMP certified laboratory at Vironoca's HQ in Stockholm, Sweden.
.png?width=775&name=Small%20face%20pictures%20(7).png)
Our vision is clear, we want to set the golden standard for safe and effective therapy development. We ensure that our clients are placing their trust in the right therapeutic candidates, by removing subjectivity from the picture. Vironova is a key niche player in the life sciences market and we are well positioned to create value in an industry with strong financial characteristics. Society is currently taking the first steps towards unleashing the full potential of gene and cell therapies. Vironova makes the journey safer by providing a clear image of the future.
Vironova Research and Innovation scientist analyzing virus image data.
Feel free to contacts us if you have any questions. You can always send an email directly to our investor relations team at ir@vironova.com.
Join us on social media
© Copyright Vironova 2020, all rights reserved